The following excerpt was taken from slide 8 of a Volpara presentation lodged 2nd September.
ARPU for VolparaEnterprise alone has been rising organically, and in FY19 was US$2.20, 37% higher than FY18. In Q1, contracts signed ranged up to an ARPU of US$7 – the aim with MRS and other products is to get to US$10 and beyond.
https://wcsecure.weblink.com.au/pdf/VHT/02142146.pdf
So we can see intention is to lift over time the average revenue per user to US$10 with the benefit of the MRS acquisition. I don’t have a break even forecast but believe the size of the opportunity makes that possible with proper execution.
- Forums
- ASX - By Stock
- General Discussion
The following excerpt was taken from slide 8 of a Volpara...
-
-
- There are more pages in this discussion • 173 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
AVH
Avita boosts skin restoration product portfolio with 'dermal matrix' – a kind of next-level gauze made of fake skin
GML
Gateway Mining sells WA Eastern Montague gold project to Brightstar for $14M – half of that in shares